- Home
- MRNA
MRNA
Moderna Inc.
as 11-15-2024 4:00pm EST
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 16.5B | IPO Year: | 2018 |
| Target Price: | $87.67 | AVG Volume (30 days): | 8.4M |
| Analyst Decision: | Hold | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.80 - $170.47 | Next Earning Date: | 11-07-2024 |
| Revenue: | $5,081,000,000 | Revenue Growth: | -44.29% |
| Revenue Growth (this year): | -51.36% | Revenue Growth (next year): | -4.53% |
Stock Insider Trading Activity of Moderna Inc. (MRNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hoge Stephen | MRNA | President | Nov 8 '24 | Sell | $46.10 | 277 | $12,771.00 | 1,443,248 | |
| Mock James M | MRNA | Chief Financial Officer | Oct 4 '24 | Sell | $60.12 | 715 | $42,985.80 | 9,505 | |
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Sep 6 '24 | Sell | $73.57 | 551 | $40,538.78 | 18,154 | |
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Aug 30 '24 | Sell | $76.99 | 114 | $8,776.75 | 18,154 | |
| Hoge Stephen | MRNA | President | Aug 30 '24 | Sell | $76.99 | 318 | $24,482.50 | 1,443,248 | |
| Mock James M | MRNA | Chief Financial Officer | Aug 28 '24 | Sell | $78.03 | 162 | $12,640.21 | 9,505 | |
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Aug 28 '24 | Sell | $78.03 | 162 | $12,640.21 | 18,154 | |
| Hoge Stephen | MRNA | President | Aug 28 '24 | Sell | $78.03 | 300 | $23,407.80 | 1,443,248 | |
| Mock James M | MRNA | Chief Financial Officer | Aug 27 '24 | Sell | $79.39 | 1,321 | $104,880.66 | 9,505 | |
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Aug 27 '24 | Sell | $79.39 | 1,319 | $104,721.87 | 18,154 |
Latest Moderna Inc. News
MRNA Breaking Stock News: Dive into MRNA Ticker-Specific Updates for Smart Investing
Investor's Business Daily
2 days ago
Pfizer, Moderna, BioNTech Take A Beating After Trump Taps Kennedy To Head Up HHS
Yahoo Finance Video
2 days ago
How analysts are reacting to RFK Jr. as Trump's HHS pick
MT Newswires
2 days ago
Update: Moderna, Novavax, Pfizer Shares Fall on Nomination of Anti-Vaxxer as US Health Secretary
Insider Monkey
2 days ago
Moderna, Inc. (MRNA): Among 12 High Growth Large Cap Stocks to Buy Now
Yahoo Finance Video
2 days ago
Trump looks to end EV credit, vaccine stocks fall on RFK JR. pick
Yahoo Finance
2 days ago
Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.
The Wall Street Journal
2 days ago
Heard on the Street: RFK Jr. Is Spooking Obesity Investors Too
FastCompany
2 days ago
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Compare MRNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRNA Moderna Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.